(Q39817550)

English

Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation

scientific article published on 3 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation (English)

1 reference

Europe PubMed Central

14 September 2017

electroporation

1 reference

based on heuristic

inferred from title

5

object named as

Young-Chul Sung

1 reference

Europe PubMed Central

14 September 2017

author name string

Sang Hwan Seo

1

1 reference

Europe PubMed Central

14 September 2017

Hyun Tak Jin

2

1 reference

Europe PubMed Central

14 September 2017

Sang Hoon Park

3

1 reference

Europe PubMed Central

14 September 2017

Je In Youn

4

1 reference

Europe PubMed Central

14 September 2017

language of work or name

0 references

publication date

3 August 2009

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

27

1 reference

Europe PubMed Central

14 September 2017

42

1 reference

Europe PubMed Central

14 September 2017

5906-5912

1 reference

Europe PubMed Central

14 September 2017

Papillomaviruses and cancer: from basic studies to clinical application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

The natural history of cervical HPV infection: unresolved issues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Prevention of cervical cancer through papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

DNA vaccines: progress and challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Spinning molecular immunology into successful immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Enhancement of immune responses to an HBV DNA vaccine by electroporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Reduced immunogenicity of DNA vaccine plasmids in mixtures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Modification of HPV 16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus--rabbit model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

IL-23 induces stronger sustained CTL and Th1 immune responses than IL-12 in hepatitis C virus envelope protein 2 DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Optimal Induction of T-Cell Responses against Hepatitis C Virus E2 by Antigen Engineering in DNA Immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

The E7 oncoprotein of high-risk human papillomavirus type 16 enters the nucleus via a nonclassical Ran-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Cross-priming as a predominant mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.07.033

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.07.033

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39817550&oldid=2090859212"